Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IL23R | Q5VWK5 | 15/20 | 0.62 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.59 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.59 |
| ▸ | MAGI3 | Q5TCQ9 | 1/20 | 0.59 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.58 |
| ▸ | KISS1R | Q969F8 | 2/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30880886 | 0.94 | IL23R (0.61) | IL23RMAGI3KISS1R | |
| SCHEMBL30471720 | 0.93 | OPRM1 (0.65) | IL23ROPRM1OPRD1PRMT1KISS1R | |
| SCHEMBL29523517 | 0.92 | PRMT1 (0.66) | IL23RMAGI3PRMT1 | |
| SCHEMBL30880899 | 0.90 | GLP1R (0.63) | — | |
| SCHEMBL30596084 | 0.89 | IL23R (0.64) | IL23ROPRM1OPRD1KISS1R | |
| SCHEMBL31683321 | 0.89 | PRMT1 (0.62) | IL23RMAGI3PRMT1KISS1R | |
| SCHEMBL29522786 | 0.89 | PRMT1 (0.62) | IL23RMAGI3PRMT1KISS1R | |
| SCHEMBL30596173 | 0.89 | IL23R (0.65) | IL23RKISS1R | |
| SCHEMBL29597475 | 0.88 | IL23R (0.61) | IL23ROPRM1OPRD1PRMT1KISS1R | |
| SCHEMBL30567715 | 0.87 | GLP1R (0.62) | IL23RKISS1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12570729-B2 | Antibody fragment based antifungal conjugate selectively targeting candida | ABGENICS LIFESCIENCES PRIVATE LIMITED (IN) | 2026-03-10 | — | — | US | disclosed |
| US-20240092878-A1 | AN ANTIBODY FRAGMENT BASED ANTIFUNGAL CONJUGATE SELECTIVELY TARGETING CANDIDA | ABGENICS LIFESCIENCES PRIVATE LIMITED (IN) | 2024-03-21 | — | — | US | disclosed |
| CN-116769027-B | anti-IL-17 nanobody, polypeptide and application thereof | 康元医疗科技(大连)有限公司 | 2023-12-01 | — | — | CN | disclosed |
| CN-116769027-A | anti-IL-17 nanobody, polypeptide and application thereof | 康元医疗科技(大连)有限公司 | 2023-09-19 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12570729-B2 | Antibody fragment based antifungal conjugate selectively targeting candida | SERPINH1, HM13, NGLY1 | IL23R 2925/4885OPRM1 4474/4885OPRD1 3916/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.